Hyunland Receives Approval for Conjunctivitis Treatment Product in China
[Asia Economy Reporter Cho Hyun-ui] Huons announced on the 31st that its Chinese joint venture, Beijing Huonland Pharmaceutical Co., Ltd. (hereinafter Huonland), recently obtained product approval from the National Medical Products Administration (NMPA) of China for the allergic conjunctivitis treatment 'Olopatadine Hydrochloride Eye Drops 0.1%.'
This product is an eye drop that alleviates symptoms caused by allergic conjunctivitis.
Based on this approval, Huonland plans to actively participate in provincial government pharmaceutical supply tenders across China starting in the fourth quarter of this year. Additionally, it will establish partnerships with distributors capable of sales and distribution throughout China to distribute the product from next year.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- "Hancom Breaks Away from Its 36-Year Mission and Formula for Success" (Comprehensive)
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
A Huons official stated, "Although the market for olopatadine hydrochloride eye drops in China is rapidly growing, prescribed treatments currently rely on a single product. Through the product launch, we aim to resolve this duopoly and make the market more flexible."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
